11.4.2. germ cell malignancy male infertility. testicular germ cell tumour (tgct) common malignancy caucasian men aged 15-40 years, affects approximately 1% sub-fertile men . lifetime risk tgct varies among ethnic groups countries. highest annual incidence tgct occurs caucasians, varies 10/100,000 (e.g., denmark norway) 2/100,000 (e.g., finland baltic countries). generally, seminomas non-seminomas preceded gcnis, untreated gcnis eventually progresses invasive cancer [1682-1684]. general decline male reproductive health increase testicular cancer western countries . almost countries reliable cancer registries, incidence testicular cancer increased . postulated related tds, developmental disorder testes caused environmental and/or genetic influences pregnancy. endocrine disrupting chemicals also associated sexual dysfunction abnormal semen parameters . cancers arise premalignant gonocytes gcnis . testicular microcalcification, seen us, associated tgct gcnis testes . 11.4.2.1. testicular germ cell cancer reproductive function men cancer must offered sperm cryopreservation prior therapeutic use gonadotoxic agents ablative surgery may impair spermatogenesis ejaculation (i.e., chemotherapy, radiotherapy retroperitoneal surgery) . men tgct decreased semen quality, even cancer treatment. azoospermia observed 24% men tgct oligospermia 50% . given average ten-year survival rate testicular cancer 98% common cancer men reproductive potential, mandatory include counselling regarding fertility preservation prior gonadotoxic treatment . patients offered ejaculated semen preservation cost-effective strategy fertility preservation, sperm extracted surgically (e.g., c/mtese). indeed, treatment tgct, including orchidectomy risk non-functioning remaining testicle, may negative impact reproductive function . shown azoospermic severely oligozoospermic, recommended men undergo sperm cryopreservation prior orchidectomy allow opportunity perform concomitant tese prior potential gonadotoxic/ablative surgery . surgical principles onco-tese differ technique tese men infertility (e.g., noa) . context, recommended organise cryopreservation care delivery networks enables referral urologist adept tese. rates under-utilisation semen analysis sperm cryopreservation reported high; resulting failure identify azoospermic severely oligozoospermic patients diagnosis may benefit advanced fertility-preserving procedures oncotese. argument performing cryopreservation prior orchidectomy may delay subsequent treatment supported contemporary clinical practice, indeed adverse impact survival investigated. context, orchidectomy unduly delayed facilities cryopreservation potential delay treatment. since chemotherapy rt teratogenic, contraception must used treatment least six months completion . chemotherapy rt impair fertility. long-term infertility rare rt dose-cumulative-dependent chemotherapy. treatment tgct result additional impairment semen quality increased sperm aneuploidy two years following gonadotoxic therapy . spermatogenesis usually recovers one four years chemotherapy . chemotherapy also associated dna damage increased sdf rate . however, sperm aneuploidy levels often decline pre-treatment levels 18-24 months treatment . several studies reviewing offspring cancer survivors shown significant increased risk genetic abnormalities context previous chemotherapy radiotherapy . addition spermatogenic failure, patients tgct leydig cell dysfunction, even contralateral testis . measurement pre-treatment levels testosterone, shbg, lh oestradiol may help stratify patients increased risk hypogonadism provide baseline post-treatment hypogonadism. risk hypogonadism may increased men treated tgct. likewise, risk hypogonadism increased survivors testicular cancer serum testosterone levels evaluated management patients . however, risk greatest 6-12 months post-treatment suggests may improvement leydig cell function treatment. therefore, reasonable delay initiation testosterone therapy, patient shows continuous signs symptoms testosterone deficiency . risk low libido erectile dysfunction also increased tgct patients . patients treated tgct also increased risk cvd . therefore, patients may require multi-disciplinary therapy approach and, context, survivorship programmes incorporating holistic view patients considering psychological, medical social needs could beneficial. patients place high value fertility potential, use testosterone therapy men symptoms suggestive tds needs balanced worsening spermatogenesis. patients consideration given use selective oestrogen receptor modulators (serms; e.g., clomiphene) gonadotrophin analogues (e.g., hcg), although off-label treatments particular clinical setting. 11.4.2.2. testicular microcalcification (tm) microcalcification inside testicular parenchyma found 0.6-9% men referred testicular us . although true incidence tm general population unknown, probably rare. ultrasound findings tm seen men tgct, cryptorchidism, infertility, testicular torsion atrophy, klinefelter syndrome, hypogonadism, disorders sex development varicocele . incidence reported seems higher high-frequency us machines . relationship tm infertility unclear, may relate testicular dysgenesis, degenerate cells sloughed inside obstructed seminiferous tubule failure sertoli cells phagocytose debris. subsequently, calcification hydroxyapatite occurs. testicular microcalcification found testes risk malignant development, reported incidence tm men tgct 6-46% [1711-1713]. systematic review meta-analysis case-control studies indicated presence tm associated ~18-fold higher odds ratio testicular cancer infertile men (pooled or: 18.11, 95% ci: 8.09, 40.55; p < 0.0001) . testicular microcalcification therefore considered pre-malignant setting patients counselled accordingly. testicular biopsies men tm found higher prevalence gcnis, especially bilateral microcalcifications . however, tm also occur benign testicular conditions microcalcification malignant. therefore, association tm tgct controversial challenge identify men risk harbouring gcnis future risk tgct. investigation association tm gcnis requires testicular biopsies large series men without signs tgct without risk factors tgct. however, clinicians patients reassured testicular cancer develop men asymptomatic tm . men potentially high-risk harbouring developing gcnis include infertility, atrophic testes, undescended testes, history tgct, contralateral tm suggested men risk factors could offered testicular biopsy . patients history tgct tm contralateral testis sub-fertile patients demonstrated increased risk gcnis , studies showing increase gcnis tm context cryptorchidism . useful algorithm proposed stratifying patients increased risk gcnis may benefit testicular biopsy. however, undertaking biopsy setting, full risks complications adopting strategy must explained patient. decastro et al., suggested testicular cancer would develop men tm (98.4%) five-year follow-up. such, extensive screening programme would benefit men significant risk. context would prudent advise patients tm risk factors testicular cancer least undergo regular testicular examination. suggested patients could also offered annual physical examination urologist us follow-up, although follow-up protocols may difficult implement invariably young cohort patients . testicular atrophy infertility association testicular cancer, authors recommend biopsy follow-up us tm seen . however, patients azoospermic undergoing therapeutic biopsy (i.e., specific purpose sperm retrieval) therefore definitive diagnosis made lack evidence demonstrating higher prevalence testicular cancer patients tm testicular atrophy. patients incidental tm, risk gcnis low logical approach instruct patients perform regular testicular self-examination. 11.4.2.3. summary evidence recommendations germ cell malignancy testicular microcalcification summary evidenceletesticular germ cell tumour (tgct) affects approximately 1% sub-fertile men.2bmen tgct frequently impaired sperm parameters diagnosis.2asemen analysis sperm cryopreservation orchidectomy allows identification tgct patients azoospermia, may benefit concomitant surgical sperm retrieval (i.e., onco-tese).2btreatment tgct result decreased sperm quality, sperm aneuploidy, increased sperm dna fragmentation (sdf), hypogonadism, sexual dysfunction cardiovascular diseases.2atesticular microcalcifications (tm) found men benign conditions (e.g., cryptorchidism, infertility, testicular torsion atrophy, klinefelter syndrome, hypogonadism, dsd, varicocele) (pre)malignant (gcnis) malignant conditions (tgct).2atesticular microcalcifications associated higher risk testicular cancer infertile men.1amen potentially risk harbouring developing gcnis include bilateral tm, infertility, atrophic testes, undescended testes, history tgct, contralateral tm.2asince tgct develop men tm, extensive screening programme invasive testicular biopsy indicated without additional risk factors.2b recommendationsstrength ratingadvise men testicular microcalcification (tm) perform self-examination even without additional risk factors, may result early detection testicular germ cell tumour (tgct).weakdo perform testicular biopsy, follow-up scrotal ultrasound (us), measure biochemical tumour markers, abdominal pelvic computed tomography, men isolated tm without associated risk factors (e.g., infertility, cryptorchidism, testicular cancer, atrophic testis).strongoffer testicular biopsy infertile men tm, belong one following higher risk groups: spermatogenic failure (infertility), bilateral tm, atrophic testes (< 12 ml), history undescended testes tgct.weakperform inguinal surgical exploration testicular biopsy offer orchidectomy multi-disciplinary team meeting discussion patient, suspicious findings physical examination us patients tm associated lesions.strongmanage men treated tgct multi-disciplinary team setting dedicated late-effects clinic survivorship program, since increased risk developing hypogonadism, sexual dysfunction cardiovascular risk.strongperform sperm cryopreservation prior planned orchidectomy additional neoadjuvant adjuvant oncological therapies.strongoffer onco-testicular sperm extraction (onco-tese) time radical orchidectomy men testicular cancer azoospermia severe abnormalities semen parameters.strong